Santhera enters into exclusive license agreement with Sperogenix Therapeutics for vamorolone in rare diseases in the Greater China Region.
Under this agreement, Sperogenix will in-license vamorolone for rare disease indications for a total consideration of up to $124 million, including a double-digit upfront cash compensation and DMD-related US-regulatory milestone payments amounting to a combined $ 20 million, as well as further double-digit royalties on net sales.
Under the terms of the agreement, Santhera will grant Sperogenix Therapeutics exclusive development and commercialization rights to vamorolone in DMD and all other rare disease indications for Greater China (including mainland China, Hong Kong, Macau, and Taiwan). Santhera will remain responsible for manufacturing and supply while Sperogenix, a China-based dedicated rare disease company financed by Lilly Asia Ventures and Morningside Ventures, will focus on regulatory and development work and future commercialization.
Sperogenix plans to initiate a regulatory filing for vamorolone for DMD in China upon US FDA approval which could lead to market entry in China as early as in 2024.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins